Low-dose rituximab ‘dampens disease activity’ in pemphigus
Australian dermatologists report a case series of eight patients with mild disease
Patients with recalcitrant pemphigus may respond to ultra-low-dose rituximab, dermatologists say.
Six of eight patients treated at Royal Melbourne Hospital responded to two off-label 200mg doses, given a fortnight apart, with clinically significant reduced disease activity at six months, they report.
